Table 1.
Assessment of the basic characteristics of the 19 included studies.
| References | Treatment | Nation | Study design | Research year range | Cases (n) | Age (years) | M/F (n) | Child-Pugh A/B/C (n) | Diameter (cm) |
|---|---|---|---|---|---|---|---|---|---|
| Shiba et al. (36) | CIRT | Japan | SRS | 2013.10–2020.3 | 11 | 65Δ (47–76)# | 8/3 | Unclear | 3.1Δ (1.5–6.5)# |
| Okazaki et al. (37) | CIRT | Japan | SRS | 2011.1–2018.12 | 9 | 80Δ (56–85)# | 7/2 | 6/3/0 | 3.4Δ (1.0–4.7)# |
| Takakusagi et al. (38) | CIRT | Japan | CR | Unclear | 2 | Case 1: 75; Case 2: 76 | Case 1: male; Case 2: male | Case 1: A; Case 2: A | Case 1: 1.3; Case 2: 2.9 |
| Shiba et al. (39) | CIRT | Japan | SRS | 2011.7–2018.8 | 11 | 76Δ (57–86)# | 9/2 | 10/1/0 | 5.3Δ (2.7–11.9)# |
| Yasuda et al. (40) | CIRT | Japan | SRS | 2008.12–2013.3 | 57 | 75Δ (49–89)# | 33/24 | 51/6/0 | 3.3Δ (1.3–9.5)# |
| Makishima et al. (41) | CIRT | Japan | CTI | Unclear | 29 | 69Δ (46–84)# | 20/9 | Unclear | 2.5Δ (1.2–10.2)# |
| Shibuya et al. (42) | CIRT | Japan | CTI | 2012.10–2016.4 | 21 | 7§(<70)#, 14§(≥70)# | 14/7 | 21/0/0 | 4.8※ (3.0–7.8)#; 11§(<5)#, 10§(≥5)# |
| Shiba et al. (43) | CIRT vs. TACE | Japan | PSMS | 2007.4–2016.9 | Total: 34; CIRT:17, TACE:17 | CIRT: 75Δ (45–85)#; TACE: 78Δ (59–90)# | CIRT: 8/9; TACE: 9/8 | CIRT: 15/2/0; TACE: 14/3/0 | CIRT: 3.0Δ (1.1–6.4)#; TACE: 3.0Δ (0.8–6.0)# |
| Shibuya et al. (44) | CIRT | Japan | SRS, MS | 2005.4–2014.11 | 174 | 73Δ (37–95)#, 67§(<70)#, 107§(≥70)# | 114/60 | 153/20/0 | 3.0Δ (0.8-10.3)#; 84§(<3)#, 90§(≥3)# |
| Shiba et al. (45) | CIRT | Japan | SRS | 2010.9–2016.12 | 68 | Sarcopenia: 77Δ (57–95)#; Non-sarcopenia: 74Δ (45–90)# |
41/27 | 57/11/0 | Sarcopenia: 3.3Δ (1.2–9.0)#; Non–sarcopenia: 3.6Δ (0.9–7.7)# |
| Toyama et al. (46) | CIRT | Japan | CR | 2014.9–2016.2 | 1 | 50 | Female | A | 5 cm |
| Shiba et al. (47) | CIRT | Japan | SRS | 2011.3–2015.11 | 31 | ≥80# | 22/9 | 27/4/0 | 4.5Δ (1.5–9.3)# |
| Kasuya et al. (48) | CIRT | Japan | CTI, CTII | 1997–2003 | 126 | 68Δ (37–84)# | 90/36 | 97/29/0 | 4.0Δ (1.0–12.0)#; 39§(≤ 3.0)#, 56§(>3.0, ≤ 5.0)#, 38§(>5.0)# |
| Harada et al. (49) | CIRT | Japan | CR | Unclear | 1 | 54 | Female | Unclear | 6 cm |
| Habermehl et al. (50) | CIRT | Germany | CTI | Unclear | 6 | 69Δ (53–78)#; 3§(<70)#, 3§(≥70)# | 3/3 | 4/1/0 | 3.5Δ (0.9 – 4.5)# |
| Komatsu et al. (51) | CIRT | Japan | SRS | 2001.5–2009.1 | 101 | 55§(<70)#, 46§(≥70)# | 73/28 | 78/20/3 | 81§(<5.0)#, 22§(5.0–10.0)#, 5§(>10.0)# |
| Imada et al. (52) | CIRT | Japan | CTI, CTII | 2000.4–2003.3 | 64 | 69Δ (37–84)# | 48/16 | 49/15/0 | 4.0Δ (1.2–12.0)# |
| Imada et al. (53) | CIRT | Japan | CTI, CTII | 1995.4–2000.3 | 43 | 66Δ (45–83)# | 29/14 | 35/8/0 | Unclear |
| Kato et al. (54) | CIRT | Japan | CTI, CTII | 1995.6–1997.2 | 24 | 64Δ (54–77)#; 4§(54–60)#, 15§(61–70)#, 5§(71–77)# | 13/11 | 16/8/0 | 5.0Δ(2.1–8.5)#; 5§(≤ 3.0)#, 9§ (>3.0, ≤ 5.0)#, 10§(>5.0)# |
CIRT, carbon ion radiotherapy; TACE, transarterial chemoembolization; PSMS, propensity-score matching study; CTI, clinical trial, Phase I; CTII, clinical trial, phase II; SRS, single-arm retrospective study; MS, multicenter study; CR, case report; M, male; F, female;
Δ
median;
#
range;
※
average;
§
number of people.